Rohrer Martin, Bauer Hans, Mintorovitch Jan, Requardt Martin, Weinmann Hanns-Joachim
Global Business Unit Diagnostic Imaging, Schering AG, Berlin, Germany.
Invest Radiol. 2005 Nov;40(11):715-24. doi: 10.1097/01.rli.0000184756.66360.d3.
RATIONALE AND OBJECTIVES: To characterize and compare commercially available contrast media (CM) for magnetic resonance imaging (MRI) in terms of their relaxivity at magnetic field strengths ranging from 0.47 T to 4.7 T at physiological temperatures in water and in plasma. Relaxivities also were quantified in whole blood at 1.5 T. METHODS: Relaxivities of MRI-CM were determined by nuclear magnetic resonance (NMR) spectroscopy at 0.47 T and MRI phantom measurements at 1.5 T, 3 T, and 4.7 T, respectively. Both longitudinal (T1) and transverse relaxation times (T2) were measured by appropriate spin-echo sequences. Nuclear magnetic resonance dispersion (NMRD) profiles were also determined for all agents in water and in plasma. RESULTS: Significant dependencies of relaxivities on the field strength and solvents were quantified. Protein binding leads to both increased field strength and solvent dependencies and hence to significantly altered T1 relaxivity values at higher magnetic field strengths. CONCLUSIONS: Awareness of the field strength and solvent associated with relaxivity data is crucial for the comparison and evaluation of relaxivity values. Data observed at 0.47 T can thus be misleading and should be replaced by relaxivities measured at 1.5 T and at 3 T in plasma at physiological temperature.
原理与目的:在生理温度下,于水和血浆中,在0.47 T至4.7 T的磁场强度范围内,对市售磁共振成像(MRI)造影剂(CM)的弛豫率进行表征和比较。还在1.5 T下对全血中的弛豫率进行了定量分析。 方法:分别通过在0.47 T下的核磁共振(NMR)光谱法以及在1.5 T、3 T和4.7 T下的MRI体模测量来测定MRI造影剂的弛豫率。纵向(T1)和横向弛豫时间(T2)均通过适当的自旋回波序列进行测量。还测定了所有试剂在水和血浆中的核磁共振频散(NMRD)曲线。 结果:量化了弛豫率对场强和溶剂的显著依赖性。蛋白质结合导致场强和溶剂依赖性均增加,因此在较高磁场强度下T1弛豫率值发生显著变化。 结论:了解与弛豫率数据相关的场强和溶剂对于弛豫率值的比较和评估至关重要。因此,在0.47 T下观察到的数据可能会产生误导,应以在生理温度下于血浆中1.5 T和3 T下测量的弛豫率数据取而代之。
J Am Chem Soc. 2005-1-19
Int J Mol Sci. 2025-6-29
Materials (Basel). 2025-5-14